RxDoctor Payments Data

Sanjay Bommakanti, MD

Internal Medicine · Surprise, AZNPI 1114111002

Payments from drug & device makers

$962in general payments, 2019–2025

Across 47 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$277
  • AstraZeneca$175
  • Abbott$118
  • Boehringer Ingelheim$117
  • Novo Nordisk$47
  • Pfizer$45
  • plus $182 from 10 others

What the payments were for

  • Food & beverage$962100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$962 in reported general payments places this provider in the 75th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$74,870
Medicare patients
260
Services billed
1,567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol44$45,039
JardianceEmpagliflozin26$34,894
EliquisApixaban30$30,430
OzempicSemaglutide20$22,049
JanuviaSitagliptin Phosphate13$19,470
XareltoRivaroxaban19$16,839
TrulicityDulaglutide11$15,626
Rosuvastatin Calcium202$4,737
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$4,708
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,124
Atorvastatin Calcium241$2,847
Albuterol Sulfate HfaAlbuterol Sulfate72$2,078
Levothyroxine Sodium152$1,360
Losartan Potassium122$1,286
Amlodipine Besylate149$1,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$175$45,03944 claims
Boehringer IngelheimJardiance$117$34,89426 claims
PfizerEliquis$45$30,43030 claims
Novo NordiskOzempic$47$22,04920 claims
Johnson & JohnsonXarelto$11$16,83919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →